Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Neuren Pharmaceuticals Limited ( (AU:NEU) ) has shared an announcement.
Neuren Pharmaceuticals Limited announced a change in the director’s interest, involving Jonathan Pilcher, who converted 1,500,000 unquoted loan-funded shares into ordinary shares. This transaction, valued at $2,760,000, reflects a strategic financial decision that could impact the company’s stock structure and potentially influence investor perceptions.
The most recent analyst rating on (AU:NEU) stock is a Buy with a A$29.75 price target. To see the full list of analyst forecasts on Neuren Pharmaceuticals Limited stock, see the AU:NEU Stock Forecast page.
More about Neuren Pharmaceuticals Limited
Neuren Pharmaceuticals Limited operates in the pharmaceutical industry, focusing on the development of therapies for neurodevelopmental disorders and neurodegenerative diseases. The company is known for its work on innovative treatments aimed at addressing unmet medical needs in these specialized areas.
Average Trading Volume: 544,918
Technical Sentiment Signal: Buy
Current Market Cap: A$1.94B
For a thorough assessment of NEU stock, go to TipRanks’ Stock Analysis page.